Sign In
Buy CTXR
$0.580
-0.0230 (-3.81%)
At Close: Jun 03, 2026
Citius Pharmaceuticals to Deliver Virtual Presentation at the Life Sciences Investor Forum
05:17pm, Monday, 22'nd Jun 2020
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that
Global Microbiology Analyzers Market Assessment and Forecast 2015-2025 - COVID-19 Updated - ResearchAndMarkets.com
12:00am, Thursday, 11'th Jun 2020
The
Citius Receives Positive FDA Feedback on Its Submitted Plan to Study Catheter Compatibility for Mino-Lok® Therapy
01:30pm, Tuesday, 02'nd Jun 2020
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that
Citius Announces Expanded Access Program for Investigational Phase 3 Mino-Lok®
12:15pm, Tuesday, 26'th May 2020
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that
Citius Announces Closing of $7.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
06:30pm, Monday, 18'th May 2020
Citius Pharmaceuticals Inc. (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced the closing of the previously announce
Should You Be Concerned About Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) Historical Volatility?
10:49am, Friday, 15'th May 2020
Anyone researching Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) might want to consider the historical volatility of the...
Citius Announces $7.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
01:00pm, Thursday, 14'th May 2020
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that it has entered into definitive a
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.62%
12:00am, Thursday, 14'th May 2020
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.62%
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that
Citius Pharmaceuticals Issues May 2020 Shareholder Letter
12:00pm, Tuesday, 12'th May 2020
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that
Digital Investor Communications Platform Proxymity Raises $20.5 Million Through Strategic Investment Round & Forms Global Consortium
01:44pm, Tuesday, 05'th May 2020
Click HERE to find out ⭐ Digital Investor Communications Platform Proxymity Raises $20.5 Million Through Strategic Investment Round & Forms Global Consortium. | Crowdfund Insider: Global Fintech New
FDA Expediting Accelerated Development of Novel Therapies for COVID-19
12:00pm, Tuesday, 28'th Apr 2020
The U.S. Federal government is working closely with companies and researchers to find treatments and vaccines to overcome the global health crisis. The FDA has been cutting red tape and has launched n
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today signed an exclu
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today the publi
